Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30

1.

Impact of herpes zoster and postherpetic neuralgia on the quality of life of Germans aged 50 or above.

Curran D, Schmidt-Ott R, Schutter U, Simon J, Anastassopoulou A, Matthews S.

BMC Infect Dis. 2018 Oct 3;18(1):496. doi: 10.1186/s12879-018-3395-z.

2.

The impact of reactogenicity after the first dose of recombinant zoster vaccine upon the physical functioning and quality of life of older adults: an open phase III trial.

Schmader KE, Levin MJ, Grupping K, Matthews S, Butuk D, Chen M, El Idrissi M, Fissette LA, Fogarty C, Hartley P, Klein NP, Nevarez M, Uusinarkaus K, Oostvogels L, Curran D.

J Gerontol A Biol Sci Med Sci. 2018 Sep 25. doi: 10.1093/gerona/gly218. [Epub ahead of print]

PMID:
30256905
3.

Cost-effectiveness of the recombinant zoster vaccine in the German population aged ≥60 years old.

Van Oorschot D, Anastassopoulou A, Poulsen Nautrup B, Varghese L, von Krempelhuber A, Neine M, Lorenc S, Curran D.

Hum Vaccin Immunother. 2018 Aug 21:1-11. doi: 10.1080/21645515.2018.1509645. [Epub ahead of print]

PMID:
30130448
4.

Development of adjuvanted recombinant zoster vaccine and its implications for shingles prevention.

Lecrenier N, Beukelaers P, Colindres R, Curran D, De Kesel C, De Saegher JP, Didierlaurent AM, Ledent EY, Mols JF, Mrkvan T, Normand-Bayle M, Oostvogels L, Da Silva FT, Vassilev V, Vinals C, Brecx A.

Expert Rev Vaccines. 2018 Jul;17(7):619-634. doi: 10.1080/14760584.2018.1495565. Epub 2018 Jul 20.

PMID:
30028651
5.

Quality of Life impact of a Recombinant Zoster Vaccine in adults ≥50 Years of Age.

Curran D, Oostvogels L, Heineman T, Matthews S, McElhaney J, McNeil S, Diez-Domingo J, Lal H, Andrews C, Athan E, Berglund J, Campora L, de Looze F, Korhonen T, Leung E, Levin M, Volpi A, Johnson RW; ZOE-50/70 study group.

J Gerontol A Biol Sci Med Sci. 2018 Jun 27. doi: 10.1093/gerona/gly150. [Epub ahead of print]

PMID:
29955836
6.

Corrigendum to "German travelers' preferences for travel vaccines assessed by a discrete choice experiment" [Vaccine 36 (2018) 969-978].

Poulos C, Curran D, Anastassopoulou A, De Moerlooze L.

Vaccine. 2018 May 31;36(23):3387. doi: 10.1016/j.vaccine.2018.04.052. Epub 2018 May 3. No abstract available.

7.

The Potential Public Health Impact of Herpes Zoster Vaccination of People Aged ≥ 50 Years in Japan: Results of a Markov Model Analysis.

Watanabe D, Mizukami A, Holl K, Curran D, Van Oorschot D, Varghese L, Shiragami M.

Dermatol Ther (Heidelb). 2018 Jun;8(2):269-284. doi: 10.1007/s13555-018-0236-3. Epub 2018 Apr 21.

8.

Incidence and costs of herpes zoster and postherpetic neuralgia in German adults aged ≥50 years: A prospective study.

Schmidt-Ott R, Schutter U, Simon J, Nautrup BP, von Krempelhuber A, Gopala K, Anastassopoulou A, Guignard A, Curran D, Matthews S, Espié E.

J Infect. 2018 May;76(5):475-482. doi: 10.1016/j.jinf.2018.02.001. Epub 2018 Feb 8.

9.

German travelers' preferences for travel vaccines assessed by a discrete choice experiment.

Poulos C, Curran D, Anastassopoulou A, De Moerlooze L.

Vaccine. 2018 Feb 8;36(7):969-978. doi: 10.1016/j.vaccine.2018.01.004. Epub 2018 Jan 12. Erratum in: Vaccine. 2018 May 3;:.

10.

Response to publication by Hoshi SL et al.: Cost-effectiveness of varicella vaccine against herpes zoster and post-herpetic neuralgia for elderly in Japan.

Curran D, Mrkvan T.

Vaccine. 2017 Dec 18;35(51):7079. doi: 10.1016/j.vaccine.2017.10.045. No abstract available.

PMID:
29195608
11.

Impact of Herpes Zoster and Post-Herpetic Neuralgia on Health-Related Quality of Life in Japanese Adults Aged 60 Years or Older: Results from a Prospective, Observational Cohort Study.

Mizukami A, Sato K, Adachi K, Matthews S, Holl K, Matsuki T, Kaise T, Curran D.

Clin Drug Investig. 2018 Jan;38(1):29-37. doi: 10.1007/s40261-017-0581-5.

12.

Economic Burden of Herpes Zoster and Post-Herpetic Neuralgia in Adults 60 Years of Age or Older: Results from a Prospective, Physician Practice-Based Cohort Study in Kushiro, Japan.

Nakamura H, Mizukami A, Adachi K, Matthews S, Holl K, Asano K, Watanabe A, Adachi R, Kiuchi M, Kobayashi K, Sato K, Matsuki T, Kaise T, Curran D.

Drugs Real World Outcomes. 2017 Dec;4(4):187-198. doi: 10.1007/s40801-017-0119-4.

13.

Should adults with diabetes mellitus be vaccinated against hepatitis B virus? A systematic review of diabetes mellitus and the progression of hepatitis B disease.

Younossi Z, Kochems K, de Ridder M, Curran D, Bunge EM, de Moerlooze L.

Hum Vaccin Immunother. 2017 Nov 2;13(11):2695-2706. doi: 10.1080/21645515.2017.1353850. Epub 2017 Jul 25. Review.

14.

Assessment of the potential public health impact of Herpes Zoster vaccination in Germany.

Curran D, Van Oorschot D, Varghese L, Oostvogels L, Mrkvan T, Colindres R, von Krempelhuber A, Anastassopoulou A.

Hum Vaccin Immunother. 2017 Oct 3;13(10):2213-2221. doi: 10.1080/21645515.2017.1345399. Epub 2017 Jul 14.

15.

The temporal impact of aging on the burden of herpes zoster.

Varghese L, Standaert B, Olivieri A, Curran D.

BMC Geriatr. 2017 Jan 23;17(1):30. doi: 10.1186/s12877-017-0420-9.

16.
17.

Vaccine Timeliness: A Cost Analysis of the Potential Implications of Delayed Pertussis Vaccination in the US.

Curran D, Terlinden A, Poirrier JE, Masseria C, Krishnarajah G.

Pediatr Infect Dis J. 2016 May;35(5):542-7. doi: 10.1097/INF.0000000000001071.

PMID:
26835971
18.

Response to publications by Heyward W et al. and Kuan R et al.: Clinical and cost-effectiveness analyses, respectively, of hepatitis B vaccination-Heplisav™ compared with Engerix-B(®) vaccine in adults.

De Ridder M, Curran D, Leroux-Roels G.

Vaccine. 2015 Jun 22;33(28):3161. doi: 10.1016/j.vaccine.2014.05.033. Epub 2014 Jun 2. No abstract available.

19.

Budget constraint and vaccine dosing: a mathematical modelling exercise.

Standaert BA, Curran D, Postma MJ.

Cost Eff Resour Alloc. 2014 Jan 22;12(1):3. doi: 10.1186/1478-7547-12-3.

20.

Quality of life analysis in patients with KRAS wild-type metastatic colorectal cancer treated first-line with cetuximab plus irinotecan, fluorouracil and leucovorin.

Láng I, Köhne CH, Folprecht G, Rougier P, Curran D, Hitre E, Sartorius U, Griebsch I, Van Cutsem E.

Eur J Cancer. 2013 Jan;49(2):439-48. doi: 10.1016/j.ejca.2012.08.023. Epub 2012 Oct 29.

21.

Surveillance to estimate the burden of rotavirus gastroenteritis in children aged less than 3 years attending day care centers in Paris, France.

Grimprel E, Garbarg-Chenon A, Pirçon JY, Curran D, Soriano-Gabarró M, Meyer N.

Hum Vaccin. 2010 May;6(5):399-406. Epub 2010 May 22.

PMID:
20431346
22.

Epidemiology of osteoporosis-related fractures in France: a literature review.

Curran D, Maravic M, Kiefer P, Tochon V, Fardellone P.

Joint Bone Spine. 2010 Dec;77(6):546-51. doi: 10.1016/j.jbspin.2010.02.006. Epub 2010 Apr 7. Review.

PMID:
20378383
23.

Quality of life of palliative chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction treated with irinotecan combined with 5-fluorouracil and folinic acid: results of a randomised phase III trial.

Curran D, Pozzo C, Zaluski J, Dank M, Barone C, Valvere V, Yalcin S, Peschel C, Wenczl M, Goker E, Bugat R.

Qual Life Res. 2009 Sep;18(7):853-61. doi: 10.1007/s11136-009-9493-z. Epub 2009 Jul 1.

24.

Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximab.

Curran D, Giralt J, Harari PM, Ang KK, Cohen RB, Kies MS, Jassem J, Baselga J, Rowinsky EK, Amellal N, Comte S, Bonner JA.

J Clin Oncol. 2007 Jun 1;25(16):2191-7. Erratum in: J Clin Oncol. 2007 Aug 20;25(24):3790.

PMID:
17538164
25.
26.

Sensitivity analysis for pattern mixture models.

Curran D, Molenberghs G, Thijs H, Verbeke G.

J Biopharm Stat. 2004 Feb;14(1):125-43.

PMID:
15027504
27.

Strategies to fit pattern-mixture models.

Thijs H, Molenberghs G, Michiels B, Verbeke G, Curran D.

Biostatistics. 2002 Jun;3(2):245-65.

PMID:
12933616
28.

What has psychiatry to contribute to industry? 1953.

Curran D.

Occup Med (Lond). 2003 Jun;53(4):290-2. No abstract available.

PMID:
12815128
29.

Multicollinearity in prognostic factor analyses using the EORTC QLQ-C30: identification and impact on model selection.

Van Steen K, Curran D, Kramer J, Molenberghs G, Van Vreckem A, Bottomley A, Sylvester R.

Stat Med. 2002 Dec 30;21(24):3865-84.

PMID:
12483772
30.

Prognostic factors for survival in adult patients with cerebral low-grade glioma.

Pignatti F, van den Bent M, Curran D, Debruyne C, Sylvester R, Therasse P, Afra D, Cornu P, Bolla M, Vecht C, Karim AB; European Organization for Research and Treatment of Cancer Brain Tumor Cooperative Group; European Organization for Research and Treatment of Cancer Radiotherapy Cooperative Group.

J Clin Oncol. 2002 Apr 15;20(8):2076-84.

PMID:
11956268

Supplemental Content

Loading ...
Support Center